EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review

Martyna Małek, Aleksandra Denkiewicz, Karolina Denkiewicz, Klaudia Pachulska, Weronika Dorosz, Maja Podolak, Michał Nawracaj, Maria Miłkowska, Julia Bartczak, Piotr Sosiński

Quality in Sport · 26.06.2026 · 60 · 72834

DOI: 10.12775/qs.2026.60.72834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 26.06.2026. Verfasst von Martyna Małek und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of themost common chronic liver diseases worldwide and is strongly linked to obesity and type 2diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attentionbecause of their hepatoprotective and cardiometabolic effects.

Aim

This narrative review summarizes current evidence on GLP-1 receptor agonists in thetreatment of MASLD and metabolic dysfunction-associated steatohepatitis (MASH).Materials and methods: A literature review was conducted using PubMed, Scopus and GoogleScholar. Included studies comprised clinical trials, randomized controlled trials, meta-analyses,review articles and international guidelines published between 2021 and 2025.

Results

Evidence suggests that GLP-1 receptor agonists, especially semaglutide andliraglutide, reduce hepatic steatosis, insulin resistance, body weight and inflammatory activityin patients with MASLD or MASH. Several studies demonstrated improvements in liverhistology and non-invasive fibrosis markers, although antifibrotic effects were less consistentin advanced cirrhosis. These agents also improved glycemic control and cardiovascular riskfactors, with an acceptable safety profile.

Conclusions

GLP-1 receptor agonists appear to be a promising therapeutic option for MASLDand MASH. However, further long-term randomized studies are required to confirm theireffects on fibrosis and liver-related outcomes.

Zitieren

APA

Małek, M., Denkiewicz, A., Denkiewicz, K., Pachulska, K., Dorosz, W., Podolak, M., Nawracaj, M., Miłkowska, M., Bartczak, J., & Sosiński, P. (2026). Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review. Quality in Sport, 60, 72834. https://doi.org/10.12775/qs.2026.60.72834

Vancouver

Małek M, Denkiewicz A, Denkiewicz K, Pachulska K, Dorosz W, Podolak M, et al. Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review. Quality in Sport. 2026;60:72834. doi:10.12775/qs.2026.60.72834

BibTeX
@article{Maek2026,
  author = {Małek, Martyna and Denkiewicz, Aleksandra and Denkiewicz, Karolina and Pachulska, Klaudia and Dorosz, Weronika and Podolak, Maja and Nawracaj, Michał and Miłkowska, Maria and Bartczak, Julia and Sosiński, Piotr},
  title = {Glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a narrative review},
  journal = {Quality in Sport},
  year = {2026},
  volume = {60},
  pages = {72834},
  doi = {10.12775/qs.2026.60.72834}
}
Kostenlos starten →